X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will advance ADARx clinical programs including ADX-324, a siRNA designed to reduce the production of PKK, a protein critical to the etiology of hereditary angioedema, and ADX-038, under development for the treatment of paroxysmal nocturnal hemoglobinuria.
Lead Product(s): siRNA Duplex Oligonucleotide
Therapeutic Area: Genetic Disease Product Name: ADX-324
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 09, 2023
Details:
The net proceeds will be used to advance ADARx’s proprietary RNA targeting platform together with novel oligonucleotide delivery technologies and to initiate phase I clinical trial of ADX-324 (siRNA duplex oligonucleotide), for the treatment of hereditary angioedema.
Lead Product(s): siRNA Duplex Oligonucleotide
Therapeutic Area: Genetic Disease Product Name: ADX-324
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ascenta Capital
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 20, 2023
Details:
ADX-324 is a short-interfering RNA (siRNA) designed to reduce the production of PKK, a protein critical to the etiology of HAE. HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks.
Lead Product(s): siRNA
Therapeutic Area: Genetic Disease Product Name: ADX-324
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
Lead Product(s): Oligonucleotide-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: SR One Capital Management
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
